Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$42.3B
sum of reported positions
Reported positions
227
Changes vs prior quarter
244
33 new · 48 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 284 measured positions in 8 quarters, the typical new or larger position finished −1.8 pts against the S&P 500 and 47% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $28.2B | $42.3B |
| Positions | 242 | 227 |
| Biggest line | — | Apple 7% |
| 5.56M |
| $1.99B |
| 4.7% |
| 2.84M | $1.65B | 3.9% |
| 1.22M | $1.41B | 3.3% |
| 493K | $1.12B | 2.7% |
| 2.36M | $1.02B | 2.4% |
| 984K | $950M | 2.2% |
| 6.71M | $937M | 2.2% |
| 2.93M | $883M | 2.1% |
| 2.13M | $805M | 1.9% |
| 3.06M | $781M | 1.8% |
| 1.92M | $685M | 1.6% |
| 1.57M | $617M | 1.5% |
| 1.73M | $611M | 1.4% |
| 1.67M | $570M | 1.3% |
| 939K | $529M | 1.3% |
| 793K | $507M | 1.2% |
| 1.56M | $451M | 1.1% |
| 2.53M | $430M | 1.0% |
| 1.15M | $418M | 1.0% |
| 538K | $411M | 1.0% |
| 2.49M | $404M | 1.0% |
| 1.97M | $368M | 0.9% |
Johnson & Johnson (JNJ)
784K shares
Cytokinetics (CYTK)
1.66M → 2.25M shares (+36%)
Akamai Technologies (AKAM)
1.3M → 1.58M shares (+22%)
Rhythm Pharmaceuticals (RYTM)
1.62M → 1.66M shares (+3%)
Caterpillar (CAT)
145K → 167K shares (+15%)
Arcutis Biotherapeutics (ARQT)
5.67M → 6.61M shares (+17%)
Amphenol (APH)
626K → 977K shares (+56%)
ServiceNow (NOW)
1.69M shares
Ascendis Pharma A (ASND)
617K shares
Onto Innovation (ONTO)
407K shares
Bridgebio Pharma (BBIO)
2.52M → 2.06M shares (−18%)
Essent Group Ltd. (ESNT)
2.55M → 2.38M shares (−7%)
Markel Group (MKL)
80K → 78K shares (−2%)
W. R. Berkley Corporation (WRB)
2.27M → 2.13M shares (−6%)
Alnylam Pharmaceuticals (ALNY)
258K → 483K shares (+87%)
Travelers Companies (The) (TRV)
478K → 420K shares (−12%)
Amgen (AMGN)
369K shares
Madrigal Pharmaceuticals (MDGL)
289K → 244K shares (−16%)
Revolution Medicines (RVMD)
1.13M → 690K shares (−39%)
Cogent Biosciences (COGT)
3.23M shares
BNY Mellon (BNY)
485K → 827K shares (+71%)
Everest Group (EG)
404K → 330K shares (−18%)
Oruka Therapeutics (ORKA)
1.05M → 1.23M shares (+17%)
MKS Instruments (MKSI)
72K → 260K shares (+261%)
Ionis Pharmaceuticals (IONS)
830K → 1.45M shares (+75%)
